Adeno-Associated Virus Vector-Based Gene Therapies Market Is Expected to Witness Growth by 2032, Estimates DelveInsight | Biomarin Pharmaceutical, Roche (Spark Therapeutics), Sangamo, Pfizer and Other

Adeno-Associated Virus Vector-Based Gene Therapies market
DelveInsight estimates that the Adeno-Associated Virus Vector-Based Gene Therapy Market, is anticipated to pick up momentum as companies across the globe are thoroughly working toward the development of new AAV-gene therapies to treat a spectrum of diseases. Leading companies such as Biomarin Pharmaceutical, Roche (Spark Therapeutics), Sangamo, Pfizer, others are involved in exploring the AAV vector-based gene therapy for a wide range of indications such as Hemophilia A and B, MPS, and others.

(New York, USA) DelveInsight’s Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market report offers a clear picture of the market position of the AAV vectors in the Gene therapy, emerging pipeline therapies, AAV vector-based Gene Therapy market share occupied by individual diseases, current and forecasted market share in the 7MM (the US, EU5 (the UK, Germany, France, Italy and Spain) and Japan) for the study period 2019-32.

The Report highlights the drivers and constraints shaping the present AAV Vector-Based Gene Therapy market along with the unmet medical needs that offer opportunities to the key players to explore the underlying potential of the market.


Request for a sample report @ Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast


Key Highlights of AAV Vector-Based Gene Therapy Market:

The Adeno-Associated Viral vector is the safest and effective vehicle that is able to maintain long-term gene and protein expression following a single injection of the vector.
Currently, two classes of recombinant AAVs (rAAVs) are in use: single-stranded AAV (ssAAV) and self-complementary AAV (scAAV). rAAV gene therapy strategies include Gene replacement, Gene silencing, Gene addition and Gene editing.
The first AAV-based gene therapy drug, Glybera, was approved by the European Medicines Agency (EMA) in 2012 but later in 2017, it was withdrawn from the market mainly due to commercial failure.
The present AAV-based Gene therapy market owns two FDA-approved AAV-based gene therapies namely, Luxturna, approved in 2017 for a rare inherited retinal dystrophy, and Zolgensma, approved in 2019 for spinal muscular atrophy.
Leading AAV Vector-Based Gene Therapy companies are Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, Audentes Therapeutics, and others.
Key indications in which the most clinical trials are ongoing include Hemophilia A, Hemophilia B, Choroideremia, Retinitis pigmentosa, Fabry disease, Pompe disease, Hunter Syndrome, Parkinson’s disease, Batten Disease, Duchenne Muscular Dystrophy (DMD), and Spinal Muscular Atrophy (SMA).
Among all the indication, Hemophilia A is expected to contribute maximally to the growth of the market size in terms of revenue by 2032 owing to a maximum number of gene therapies with mostly in late phase of development, which are expected to enter into the market, the precedence of existing high treatment cost and also expected high cost for these upcoming gene therapies and also significant residual unmet need.
Whereas among the emerging AAV gene therapies, Valoctocogene Roxaparvovec (BMN 270) expected to generate the maximum revenue by 2032 in the 7MM from the haemophilia A owing to visibility around the clinical profile and also early mover advantage.


Know more about the report highlights @


Adeno-Associated Virus (AAV) Overview

Adeno-associated virus hails from the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small viruses (25-nm) with a genome of single-stranded DNA (~4.7 kb) that can either be the plus (sense) or minus (anti-sense) strand. AAV is replication-defective and depends on a helper virus for effective and productive replication in mammalian cells. However, for choosing AAV as a gene delivery vector depends on:

which cell/tissue types are being targeted;
the safety profile associated with the delivered gene;
the choice of systemic versus local delivery; and
the use of tissue-specific or constitutively active promoters.


Adeno-associated virus (AAV) Vector-Based Gene Therapy

With advances in bioengineering and genetics, the horizon of the medical approaches giving rise to novel treatment options, such as Gene therapy has also widened. Gene therapy has emerged out as a promising treatment approach for a number of inherited disorders, certain types of cancer, and certain viral infections. The delivery of gene therapy involves “vectors” which can be either viral or non-viral vectors. Out of the several viral vectors, Adeno-associated virus (AAV) vectors are currently among the most frequently used, safest and effective viral vectors for gene therapy delivery. AAV vectors are the leading viral vectors for gene delivery to treat a variety of human diseases.


Key Indications Covered:

Hemophilia A
Hemophilia B
Retinitis pigmentosa
Lysosomal Storage Disorders
Fabry disease
Pompe disease
Hunter Syndrome
Parkinson’s disease
Neurological Disorders
Batten Disease
Duchenne Muscular Dystrophy (DMD)
Spinal Muscular Atrophy (SMA)


Request for sample report @


Epidemiology Segmentation

In the year 2020, the total prevalent cases of selected indications in which AAV Gene Therapies were administered were estimated to be 2,863,103 in the 7MM. DelveInsight’s Adeno-Associated Virus Vector-Based Gene Therapy Market Report provides historical as well as forecasted epidemiological analysis for the study period 2019-32 for the 7MM segmented into:

Total prevalent cases of selected indications (Hemophilia A, Hemophilia B, Fabry disease, Pompe disease, Choroideremia, Retinitis Pigmentosa, Hunter syndrome, Batten disease, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Parkinson’s disease) in the 7MM [2019-2032] Total Indication wise eligible cases in the 7MM [2019–2032] Indication wise Treated Cases of AAV Gene Therapies in the 7MM [2019–2032]


Adeno-Associated Virus Vector-Based Gene Therapy Market

At the moment, the AAV Vector-Based Gene Therapy Market has only two FDA-approved AAV vector-based gene therapies approved.

Spark Therapeutics’ Luxturna is approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. It is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease and the first AAV vector gene therapy approved in the United States.

Another therapy occupying the market share is Novartis/AveXis’s Zolgensma, an AAV-delivered gene therapy indicated for the treatment of paediatric patients

However, before Luxturna and Zolgensma managed to steal the spotlight in the AAV Vector-Based Gene Therapy Market, there was another candidate, Glybera, which got the nod from the EMA to treat an ultra-rare, hereditary lipoprotein lipase deficiency (LPLD); and became the first Gene therapy to get launched. However, the decision of the company to not renew its market authorization after it expired in October 2017 stresses on the cost of the maintenance and development of the gene therapies even if they prove to be outright cures.


Visit, Adeno-Associated Virus Vector-Based Gene Therapy Market, for more information @


Key Pipeline Adeno-Associated Virus Vector-Based Gene Therapies:

Valoctocogene Roxaparvovec (BMN 270): BioMarin Pharmaceutical: Phase III
PF-06939926: Pfizer: Phase III
Fidanacogene elaparvovec: Pfizer (initiated by Spark Therapeutics): Phase III
AMT-061: uniQure/CSL Behring: Phase III
Timrepigene emparvovec (BIIB111): NightstaRx Ltd, a Biogen Company: Phase III
Giroctocogene fitelparvovec (SB-525): Pfizer (previously Sangamo Biosciences): Phase III
BIIB112 (AAV8-RPGR): NightstaRx Ltd, a Biogen Company: Phase II/III
NLX P101 (AAV-GAD): MeiraGTx: Phase II
VY-AADC (NBIb-1817/ AAV2-hAADC): Neurocrine Biosciences/ Voyager Therapeutics: Phase II
SPK-8011: Roche (previously Spark Therapeutics)/Pfizer: Phase I/II
ST-920: Sangamo Therapeutics: Phase I/II
FLT190: Freeline Therapeutics: Phase I/II
SPK-3006 (AAV-sec-GAA): Spark Therapeutics: Phase I/II
ACTUS-101: Asklepios Biopharmaceutical (Actus Therapeutics): Phase I/II
AT845: Audentes Therapeutics: Phase I/II
SRP-9001: Roche/Sarepta Therapeutics: Phase I/IIa
HORA-PDE6B: Horama S.A.: Phase I/II
AAV-RPGR (AAV2/5-RPGR): MeiraGTx UK II Ltd: Phase I/II
RGX-121: RegenxBio: Phase I/II
SB-913: Sangamo Therapeutics: Phase I/II
AT-GTX-501 (scAAV9.CB.CLN6): Amicus Therapeutics: Phase I/II
AT-GTX-502 (scAAV9.P546.CLN3): Amicus Therapeutics: Phase I/II


There is not a shred of doubt that clinical successes in AAV-mediated gene replacement have helped Adeno-Associated Viruses to get recognized as an ideal therapeutic vector for delivery of gene therapies. With two AAV vector-based gene therapies having won regulatory approval, their popularity as the predominant vectors that deliver genes of interest to target tissues with improved specificity, efficiency, and safety in the Gene therapy market further fuelled. However, the production and formulation of AAV products require specified conditions so as to ensure good stability and yield, and even after caution, some of its processing methods (filtration or lyophilization) may lead to aggregation or loss of AAV titer. Further, storing the AAV products can also prove to be quite challenging.

Conclusively, Gene therapy has proved to be an ingenious tool in the healthcare sector and with dramatic advancements being made in the domain, its potential is unfolding at a rapid pace. Thus, it is not wrong to say that Gene therapy is set to emerge as a novel therapeutic option.


Scope of the Adeno-Associated Virus Vector-Based Gene Therapies report:

Geography Coverage: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
Study Period: 3-year historical and 11-year forecasted analysis (2019-2032).
Adeno-Associated Virus Vectors in Gene Therapy Market Segmentation: By Selected Indication Patient Pool, Market Size by Therapies, Market Size by Indication, Market Size by Country
Key Players Involved: BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx UK II Ltd, Horama S.A, Sarepta Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Asklepios Biopharmaceutical, Spark Therapeutics, and several others.
Analysis: Comparative and conjoint analysis of Adeno-Associated Virus Vectors in Gene Therapy Emerging therapies
Tools used: SWOT analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Case Studies
KOL’s Views
Analyst’s Views


Request for Sample report @


Table of Content

1.  Key Insights

2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy

3. Competitive Intelligence Analysis for AAV Vector-Based Gene Therapy Market

4. AAV Vector-Based Gene Therapy Market SWOT Analysis

5. Adeno-Associated Virus Vector-Based Gene Therapy Market Overview at a Glance

6. Adeno-Associated Virus Vector-Based Gene Therapy: Disease Background and Overview

7. Patient Journey

8. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population

9. AAV Vector-Based Gene Therapy Market: Treatment Algorithm, Current Treatment, and Medical Practices

10. AAV Vector-Based Gene Therapy Market Unmet Needs

11. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment

12. Marketed Products in AAV Vector-Based Gene Therapy Market

13. Emerging Adeno-Associated Virus Vector-Based Gene Therapies

14. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis

15. Attribute analysis

16. Adeno-Associated Virus Vector-Based Gene Therapy Market Outlook: 7MM

17. Access and Reimbursement Overview of Adeno-Associated Virus Vector-Based Gene Therapy Market

18.  KOL Views

19. Adeno-Associated Virus Vector-Based Gene Therapy Market Drivers

20. Adeno-Associated Virus Vector-Based Gene Therapy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: